Miranda Toledano, MBA, has over 20 years of biotech executive leadership, principal investment, and capital market experience. Since 2018, Miranda served as Chief Operating Officer, Chief Financial Officer and a Board Member of TRIGR Therapeutics an oncology focused antibody company, which was acquired by Compass Therapeutics in June 2021. Previously, Ms. Toledano served on the executive management team of Sorrento Therapeutics as Executive Vice President Corporate Development, where she helped drive the Company’s oncology, cellular therapy, and pain franchises. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings totaling over $4 billion in aggregate value. Prior to joining MLV, Ms. Toledano served as a VP in the investment group of Royalty Pharma. Ms. Toledano also serves as a Director of Entera Bio and Lipomedix Pharmaceuticals Ltd.
Ms. Toledano holds a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.